# Pizarra — PT-pseudo_3cc88c81f35a (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3cc88c81f35a
Task: 1

Encounter: Urology - outpatient on 27 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 8.3 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.206 ng/mL²
  - PSA velocity: 0.78 ng/mL/yr
  - Prior PSA: 6.7 ng/mL
  - Prostate volume: 40.2 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.69907415 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 8.3 ng/mL. PI-RADS 2. PSAD 0.21. Prostate volume 40 mL. DRE nodus. csPCa 0.70.

Vitals: weight 85 kg, height 180 cm, BMI 26.2, BP 114/76 mmHg, HR 88 bpm. Smoking: Ex-smoker (11 pack-yr, quit 2010).

Chief complaint: Clinical review sought after a previous prostate biopsy and a recent PSA increase to 8.3 ng/mL.

History: He is a 66-year-old man initially flagged for an elevated PSA during routine primary care screening in 2023. Subsequent monitoring involved serial blood work and a previous biopsy that returned Positive for low-grade disease. He works as a retired warehouse worker, remains married, and shares a multi-generational household with his spouse and an adult child. Daily life revolves around gardening rather than formal exercise. He is an Ex-smoker (11 pack-yr, quit 2010), while alcohol intake remains minimal at roughly one unit weekly. He experiences occasional mild urinary hesitancy and nocturia, corresponding to an IPSS score of 17, yet explicitly denies bone pain, unexplained weight loss, or haematuria. Comorbidities: none. Active medication: None.

Physical examination: DRE: firm, asymmetrically enlarged prostate with a discrete Nodus palpable in the left peripheral zone. The rest of the abdominal and cardiovascular evaluation remains unremarkable, documenting a blood pressure of 114/76 mmHg and a steady heart rate of 88 bpm. Overall, he presents as well-appearing without pallor or peripheral lymphadenopathy.

Patient info: retired warehouse worker; Married; Lives with adult child (multi-generational household).
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 1 units / week; exercise Gardening, no structured exercise; IPSS score: 17/35 (moderate LUTS).


Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.43 +/- 0.22   (95% CI 0.06-0.87)

Where the uncertainty comes from:
  - aleatoric  dA = 0.20  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.10  (few labelled cases resemble this one)
  - 3.1 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=2.0, bx_ord=3.0, psa=8.3, age=66.0, psad=0.206, dre_ord=1.0, vol=40.2, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=2, PSA=8.3, PSA density=0.206, DRE=Nodus, csPCa probability=0.699) and failed to incorporate the critical context of the prior positive biopsy result. It did not weigh the significance of the prior positive diagnosis against the current findings.

WHY THE SUGGESTION COULD BE WRONG
The prior suggestion of "NO BIOPSY" has a wide uncertainty interval (0.43 +/- 0.22), meaning the classifier is genuinely unable to distinguish between biopsy and no biopsy based on the limited input. Specifically, the prior ignores the clinical dilemma: a rising PSA (8.3 from 6.7) combined with a prior positive biopsy, which the EXPERT-PROTOCOL noted is undetermined by the visible panel alone. The prior cannot account for the uncertainty inherent in the guideline criterion.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context on prior biopsy findings
laboratory panel - full panel
previous notes - context on prior biopsy findings

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Subject: Multiparametric MRI of the Prostate | Ziekenhuis Gelderse Vallei, Ede | 24 January 2025
The gland measures 40.2 mL in total volume, appearing homogeneous on T2-weighted imaging with mild transition zone enlargement. A roughly 6 mm well-defined nodule with benign characteristics occupies the anterior transition zone apex. The peripheral zone lacks any focal T2-hypointense lesions. Symmetric diffusion is observed on DWI, showing no restricted uptake, while dynamic contrast enhancement remains negative for early focal signals. There is no evidence of extraprostatic extension, seminal vesicle invasion, or suspicious pelvic lymphadenopathy.
get_psa_trend
[{"date": "May 2023", "val": 2.5}, {"date": "Dec 2023", "val": 4.2}, {"date": "Jul 2024", "val": 7.2}, {"date": "Jan 2025", "val": 8.3}]
get_previous_notes
[{"date": "01 Jun 2024", "author": "Dr. M. Jansen (GP)", "text": "Serial screening detected a PSA value of 6.7 ng/mL, marking a modest rise from the preceding 6.4 ng/mL measurement. Aside from occasional mild urinary frequency, he experiences no lower urinary tract symptoms. A follow-up blood draw was planned for late summer to track the trend prior to any specialist involvement."}, {"date": "29 Sep 2024", "author": "Dr. M. Jansen (GP)", "text": "Clinical review focused on the persistent PSA elevation. Latest labs indicate a further climb to 8.3 ng/mL alongside a %free PSA reading of 18%. Consequently, a urology outpatient appointment was booked for comprehensive assessment, and prior scan and biopsy records were requested for the visit."}]
get_lab_results
PSA: 8.3 ng/mL (24 Dec 2024, H); %Free PSA: 18% (24 Dec 2024, L)
get_family_history
Unknown

WHAT NOT RETRIEVED
The pathology report was not retrieved, which is necessary to determine the ISUP grade or Gleason score of the prior positive biopsy.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling:
- PSA velocity is 0.78 ng/mL/yr, indicating a significant recent rise.
- The patient has a prior positive biopsy for low-grade disease, suggesting ongoing disease monitoring is required.
- The %Free PSA is 18%, which is borderline, though the context of the prior biopsy is missing.

AGAINST Sampling:
- The mpMRI shows a PI-RADS score of 2, indicating a low-risk lesion, and no PI-RADS 3+ lesion was identified.
- The MRI shows no evidence of extraprostatic extension or seminal vesicle invasion.

WHERE THIS LEANS
The evidence is divided: the rising PSA and prior positive biopsy suggest a need for further characterization, but the low PI-RADS score and lack of aggressive features argue against immediate biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: uncertain)

The statistical prior suggested no biopsy, but the clinical situation is complicated by a prior positive biopsy and a rising PSA (8.3 ng/mL from 6.7 ng/mL). Since the retrieved documents do not document the prior ISUP grade or provide a comparison against a named previous MRI, the decision remains unclear. Therefore, proceeding with a biopsy is warranted to characterize the known cancer before proceeding to definitive treatment planning.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
